Posted at 16:59h
in
Blog,
Business
Montreal / April 21, 2023 - NexPlasmaGen announces that it has received $511,186 in funding from the ministère de l'économie, de l'innovation et de l’Énergie (MEIE) du Québec and the Québec Breast Cancer Foundation (QBCF) to conduct clinical safety trials with its Convertible Plasma Jet...
NEXPLASMAGEN TO PRESENT AT THE 2023 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/February 2, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2023 OBIO Investment Summit.
The OBIO Investment Summit will be hosted at the World Trade Centre Toronto on February...
Montreal / July 4, 2022
NexPlasmaGen is a finalist for the ADRIQ Innovation Award 2022 in the category Innovation from Public Research. The Innovation Awards Gala has become a must-attend event in the Quebec ecosystem.
The 32nd ADRIQ Innovation Awards Gala will take place on Thursday, November...
Montreal/June 23, 2022 – NexPlasmaGen is honored to present at the MedInvest Oncology Investor Conference.
The MedInvest Oncology Investor Conference will be hosted in person June 28-29, 2022 in New York City at the One Vanderbilt Avenue. NexPlasmaGen was selected to present on June 28 at...
NEXPLASMAGEN TO PRESENT AT THE 2022 OBIO INVESTMENT SUMMIT
Canada’s Premier Health Science Investment Event!
Montreal/January 30, 2022 – NexPlasmaGen is proud to announce that it is presenting at 2022 OBIO Investment Summit.
The OBIO Investment Summit will be hosted virtually February 9-11, 2022, and NexPlasmaGen was selected...
NEXPLASMAGEN TO PRESENT AT SEED SHOWCASE 2022
NexPlasmaGen will pitch its business opportunity to investors!
Montreal/December 24 – NexPlasmaGen, today announced that it is presenting at Seed Showcase, part of the Biotech Showcase™ 2022 conference. This year, in addition to seeing NexPlasmaGen scheduled presentation delivered onsite via...